Review
Effectivity and safety profile of tenapanor, a sodium-hydrogen exchanger isoform 3 inhibitor, as an innovative treatment for hyperphosphatemia in chronic kidney disease: A systematic review of clinical studies
Perfil de efectividad y seguridad de tenapanor, un inhibidor de la isoforma 3 del intercambiador de sodio/hidrógeno, como tratamiento innovador para la hiperfosfatemia en la enfermedad renal crónica, una revisión sistemática de estudios clínicos
William Suciangtoa,
, Haerani Rasyidb, Anastasya Angelica Vicentec, Winny Suciangtoa
Corresponding author
a Department of Medical Doctor Study Program, Faculty of Medicine, Hasanuddin University, Makassar City, South Sulawesi Province, Indonesia
b Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar City, South Sulawesi Province, Indonesia
c Department of Physiology, Faculty of Medicine, Hasanuddin University, Makassar City, South Sulawesi Province, Indonesia
Read
4675
Timeswas read the article
1737
Total PDF
2938
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2026 1 | 167 | 140 | 307 |
| 2025 12 | 441 | 273 | 714 |
| 2025 11 | 421 | 155 | 576 |
| 2025 10 | 306 | 100 | 406 |
| 2025 9 | 177 | 78 | 255 |
| 2025 8 | 186 | 128 | 314 |
| 2025 7 | 177 | 70 | 247 |
| 2025 6 | 231 | 278 | 509 |
| 2025 5 | 146 | 79 | 225 |
| 2025 4 | 73 | 53 | 126 |
| 2025 3 | 134 | 97 | 231 |
| 2025 2 | 111 | 85 | 196 |
| 2025 1 | 258 | 138 | 396 |
| 2024 12 | 110 | 63 | 173 |
Show all
